|
Q-767
|
Thursday, January 22, 2026 |
With regard to Health Canada, the Public Health Agency of Canada, Innovation, Science and Economic Development Canada, reports of myocarditis and pericarditis following COVID-19 vaccination and the March 3, 2021, International Regulatory Meeting for Pharmacovigilance Cluster on myocarditis following COVID-19 vaccination, at which Canada was represented: (a) what data were provided at this meeting in relation to myocarditis and pericarditis reports; (b) who attended this meeting on behalf of Canada; (c) what was the conclusion of the cluster meeting and did Health Canada agree with this conclusion; (d) whether the answer to (c) is affirmative or negative, what was Health Canada's rationale; (e) following this meeting, (i) what was Health Canada's action plan, (ii) was there a plan to investigate this signal further by Health Canada or any other regulatory body, and, if so, when, by whom and what was the plan; (f) were there meetings between Health Canada and other international regulatory agencies and the Marketing Authorization Holder, and, if so, what terms and conditions were placed upon the vaccine companies by Health Canada in relation to the reports of myocarditis and pericarditis; (g) what actions were taken by Health Canada or the Public Health Agency of Canada to identify cases of myocarditis or pericarditis following COVID-19 immunization in Canada with respect to (i) diagnostic parameters, (ii) research, (iii) reporting from health care providers, (iv) provincial guidance; and (h) for communications regarding the risk of myocarditis and pericarditis following COVID-19 vaccination for the public, (i) what input from non-government organizations and institutions was considered for public and media communications and messaging, (ii) what were the dates of the communication, (iii) what strategies and media scripts were developed, (iv) where are these communications posted or archived, (v) how and when was guidance to health care professionals updated to ensure informed consent with respect to myocarditis and pericarditis following COVID-19 vaccination? |
Answered |
Wednesday, March 11, 2026 |
|
Q-766
|
Thursday, January 22, 2026 |
With regard to Health Canada, the Public Health Agency of Canada and reports of myocarditis and pericarditis following COVID-19 vaccination: (a) what is the standard operating procedure when an Adverse Event Following Immunization report containing a potential safety signal is received or identified; (b) what federal teams, working groups, contract companies and persons were responsible for requesting, receiving, reviewing and monitoring any Adverse Event Following Immunization reports with respect to myocarditis and pericarditis following the COVID-19 vaccines from (i) international sources, (ii) the provinces and territories; (c) after the information in (b) was received, what steps or actions were taken next, by whom, and on what date; (d) was the Public Health Agency of Canada or Health Canada notified of Adverse Event Following Immunization reports for myocarditis and pericarditis following COVID-19 vaccination, and, if so, for each notification, what was the (i) name of the notifier, (ii) title of the notifier, (iii) form of notification, (iv) name of the person who was notified, (v) date of the notification; (e) did the Public Health Agency of Canada or Health Canada receive the initial reports of myocarditis and pericarditis following COVID-19 vaccination from the Israeli Ministry of Health in February 2021, and, if so, (i) who received the notification, (ii) what was the date of the notification, (iii) what actions were taken after the notification, (iv) who authorized these actions, including their name, their title and the date of authorization; (f) for each communication between the Public Health Agency of Canada, Health Canada and all Public Health Agency of Canada or Health Canada COVID-19 task forces or working groups related to the Israeli Ministry of Health myocarditis and pericarditis safety signal notification, what was the (i) date, (ii) subject, (iii) type and content, of the communication; and (g) what communication related to the myocarditis and pericarditis safety signal occurred between the Public Health Agency of Canada, Health Canada or the Public Health Agency of Canada or Health Canada COVID-19 task forces and the COVID-19 vaccine manufacturer, including the (i) date, (ii) subject, (iii) type and content, of the communication? |
Answered |
Wednesday, March 11, 2026 |
|
Q-605
|
Monday, November 24, 2025 |
With regard to the Royal Canadian Mounted Police Firearms Compensation Program Web Portal and Case Management System, as referenced in the Supplementary Estimates (B), 2025-26 : (a) since the creation of the web portal and case management system, what are the total costs incurred to date to operate, service, and maintain the system; (b) what are the yearly costs associated with system upkeep, including software updates, technical support, licensing, security, and any related operating expenses; (c) were any outside third-party companies contracted to design, develop, operate, maintain, or upgrade the web portal or case management system, and, if so, what are the details of all such contracts, including (i) the vendor, (ii) the amount, (iii) the date of the contract, (iv) the duration of the contract, (v) the purpose of the contract, (vi) whether the contract was sole-sourced or competitively awarded; (d) what problems, outages, technical failures, or performance issues have been identified since the launch, and what were the associated costs to remediate them; and (e) what future spending is planned or budgeted for the continued operation, maintenance, or upgrading of the system? |
Answered |
Monday, January 26, 2026 |
|
Q-603
|
Monday, November 24, 2025 |
With regard to contracts between government departments, agencies or Crown corporations and the Brookfield Corporation or any of Brookfield's subsidiaries: (a) what are the details of all new contracts signed since January 1, 2025, including, for each, the (i) date, (ii) value, (iii) vendor, (iv) description of the goods or services, (v) manner in which the contract was awarded (sole-sourced or competitive bid); (b) for each contract in (a), was ministerial approval required, and, if so, which minister approved the contract; (c) for each contract in (a) where ministerial approval was not required, who approved the contract; and (d) what are the details of all contracts, new or existing, where the value of the contract rose
since January 1, 2025, including, for each, the (i) date of the original contract, (ii) vendor, (iii) description of the goods or services, (iv) original contract value, (v) current contract value, (vi) date the contract value was increased, (vii) name and title of the minister, or official if ministerial approval was not required, that approved the increase? |
Answered |
Monday, January 26, 2026 |
|
Q-164
|
Thursday, June 12, 2025 |
With regard to the Canada Border Services Agency, Immigration, Refugees and Citizenship Canada, and the COVID-19 pandemic: (a) how many migrant workers entered Canada between (i) April 1, 2020, and October 31, 2020, (ii) April 1, 2021, and October 31, 2021, (iii) April 1, 2022, and October 31, 2022, broken down by province; (b) what are the details of the quarantine period, including (i) how many migrant workers were quarantined, by province, (ii) when they were quarantined, by month and year, (iii) the length of the quarantine period, (iv) who paid for their quarantine accommodations, (v) the overall cost to the government; (c) how many migrant workers received their COVID-19 vaccine in Canada, upon their arrival in Canada between (i) April 1, 2020, and October 31, 2020, (ii) April 1, 2021, and October 31, 2021, (iii) April 1, 2022, and October 31, 2022, broken down by province; (d) in cases where the migrant worker was already COVID-19
vaccinated in his or her country of origin, did Canadian immigration authorities document the date
of vaccination and the vaccine brand for migrant workers, and what is the data; (e) in cases where the migrant worker received an unapproved COVID-19 vaccine brand prior to entry, would they require receipt of a Canadian approved brand upon entry; (f) following COVID-19 immunization, how many migrant workers (i) sought medical attention, (ii) were determined too ill to work, (iii) were hospitalized, (iv) died while in Canada; (g) for each case in (f)(i) to (f)(iv), how many occurrences were there between (i) April 1, 2020, and October 31, 2020, (ii) April 1, 2021, and October 31, 2021, (iii) April 1, 2022, and October 31, 2022, broken down by province; (h) in cases where a migrant worker died following immunization, what were the causes of death; (i) with regard to persons in (h), were
any autopsies performed on any deceased migrant workers; (j) if the answer to (i) is affirmative, how many autopsies were performed and what were the findings; (k) how many deceased bodies or their cremated remains were sent back to their country of origin between (i) April 1, 2020, and October 31, 2020, (ii) April 1, 2021, and October 31, 2021, (iii) April 1, 2022, and October 31, 2022; and (l) in cases where a migrant worker had an adverse event following their COVID-19 vaccination in Canada, would they qualify for Canada's Vaccine Injury Support Program? |
Answered |
Monday, September 15, 2025 |
|
Q-154
|
Wednesday, June 11, 2025 |
With regard to communications between the Minister of Justice, or Attorney General of Canada, or their office, and the Chief Justice of the Supreme Court of Canada, or that office, since March 2020:
what are the details of all such communication, including, for each, the (i) date, (ii) format, (iii) sender, (iv) recipient, (v) title, (vi) subject matter, (vii) decisions made, if applicable? |
Answered |
Monday, September 15, 2025 |
|
Q-141
|
Tuesday, June 10, 2025 |
With regard to the Vaccine Injury Support Program: (a) what are the total expenditures to date related to the program, broken down by year since the program was formed; (b) what is the yearly breakdown of expenditures by type of expense, including (i) compensation payments, (ii) overhead, excluding salaries, (iii) lawyers, (iv) salaries, (v) other types of expenditures, broken down by type; and (c) what are the details of all contracts over $5,000 signed in relation to the program, including, for each, the (i) date, (ii) vendor, (iii) value or amount, (iv) description of the goods or services, (v) type of contract (consulting, payments for goods, etc.), (vi) manner in which the contract was
awarded (sole-sourced or competitive bid)?
|
Answered |
Monday, September 15, 2025 |
|
Q-140
|
Tuesday, June 10, 2025 |
With regard to expenditures on consulting services by the government in the 2024 calendar year, broken down by department, agency or other government entity: (a) what was the total amount spent on (i) training consultants (code 0446), (ii) information technology and telecommunications consultants (code 0473), (iii) management consulting (code 0491), (iv) other types of consultants or consulting, broken down by type and object code; and (b) for each response in (a), what is the total value of the expenditures that were (i) awarded competitively, (ii) sole-sourced? |
Answered |
Monday, September 15, 2025 |
